The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Phase I/II Trial of Intravenous NDV-HUJ Oncolytic Virus in Recurrent Glioblastoma Multiforme
Open accessAbstract
We undertook a Phase I/II trial in patients with apparent recurrent glioblastoma multiforme (GBM) based on imaging studies to determine the safety and tumor response of repetitive intravenous administration of NDV-HUJ, the oncolytic HUJ strain of Newcastle disease virus. The first part of the study utilized an accelerated intrapatient dose-escalation protocol with one-cycle dosage steps of 0.1, 0.32, 0.93, 5.9, and 11 billion infectious units (BIU) of NDV-HUJ (1 BIU = 1 x 10(9) EID(50) 50% egg infectious dose) followed by three cycles of 55 BIU. Virus was administered by intravenous infusion over 15 min. In the second part, patients received three cycles of 11 BIU. All patients without progressive disease were maintained with two doses of 11 BIU iv weekly. Eleven of the 14 enrolled patients (11-58 years, Karnofsky performance scale 50-90%) received treatment. Toxicity was minimal with Grade I/II constitutional fever being seen in 5 patients. Maximum tolerated dose was not achieved. Anti-NDV hemagglutinin antibodies appeared within 5-29 days. NDV-HUJ was recovered from blood, saliva, and urine samples and one tumor biopsy. One patient achieved a complete response. Intravenous NDV-HUJ is well tolerated. The findings of good tolerability and encouraging responses warrant the continued evaluation of NDV-HUJ in GBM, as well as other cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A simple method of estimating 50 per cent end points
Muench, H. (1938) · Medical Entomology and Zoology · Cited by 8,376
Response criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
Application of a Microtechnique to Viral Serological Investigations
Sever, J. L. (1962) · The Journal of Immunology · doi:10.4049/jimmunol.88.3.320 · Cited by 1,614
Markert, J. M., Medlock, M. D., Rabkin, S. D., Gillespie, G. Y., Todo, T., Hunter, W. D., Palmer, C. A., Feigenbaum, F., Tornatore, C., Tufaro, F., et al. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301205 · Cited by 976
Nutt, C. L., Mani, D. R., Betensky, R. A., Tamayo, P., Cairncross, J. G., Ladd, C., Pohl, U., Hartmann, C. J., McLaughlin, M. E., Batchelor, T. T., et al. (2003) · PubMed · Cited by 959
Yung, W. K. A., Albright, R. E., Olson, J., Fredericks, R., Fink, K., Prados, M. D., Brada, M., Spence, A., Hohl, R. J., Shapiro, W., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1316 · Cited by 929
Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials
Wong, E. T., Hess, K. R., Gleason, M. J., Jaeckle, K. A., Kyritsis, A. P., Prados, M. D., Levin, V. A., & Yung, W. K. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2572 · Cited by 902
Natural Interferon α/β–Producing Cells Link Innate and Adaptive Immunity
Kadowaki, N., Antonenko, S., Lau, J. Y.-N., & Liu, Y.-J. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.219 · Cited by 849
Accelerated Titration Designs for Phase I Clinical Trials in Oncology
Simon, R., Rubinstein, L., Arbuck, S. G., Christian, M. C., Freidlin, B., & Collins, J. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.15.1138 · Cited by 639
Kirn, D., Martuza, R. L., & Zwiebel, J. (2001) · Nature Medicine · doi:10.1038/89901 · Cited by 502
Davis, F. G., Freels, S., Grutsch, J., Barlas, S., & Brem, S. (1998) · Journal of Neurosurgery · doi:10.3171/jns.1998.88.1.0001 · Cited by 482
Chiocca, E. A., Abbed, K. M., Tatter, S., Louis, D. N., Hochberg, F. H., Barker, F., Kracher, J., Grossman, S. A., Fisher, J. D., Carson, K., et al. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.021 · Cited by 436
Pecora, A. L., Rizvi, N., Cohen, G. I., Meropol, N. J., Sterman, D., Marshall, J. L., Goldberg, S., Gross, P., O’Neil, J. D., Groene, W. S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.042 · Cited by 385
Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse
Brada, M., Hoang-Xuan, K., Rampling, R., Dietrich, P.-Y., Dirix, L. Y., Macdonald, D., Heimans, J. J., Zonnenberg, B. A., Bravo-Marques, J. M., Henriksson, R., et al. (2001) · Annals of Oncology · doi:10.1023/a:1008382516636 · Cited by 372
Phuong, L. K., Allen, C., Peng, K. W., Giannini, C., Greiner, S. M., TenEyck, C. J., Mishra, P. K., Macura, S. I., Russell, S. J., & Galanis, E. (2003) · PubMed · Cited by 248
Targeted Molecular Therapy of GBM
Mischel, P. S., & Cloughesy, T. F. (2003) · Brain Pathology · doi:10.1111/j.1750-3639.2003.tb00006.x · Cited by 247
Development of novel targeted therapies in the treatment of malignant glioma
Rich, J. N., & Bigner, D. D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1380 · Cited by 247
Newcastle disease virus (NDV): brief history of its oncolytic strains
Sinkovics, J. G., & Horvath, J. C. (2000) · Journal of Clinical Virology · doi:10.1016/s1386-6532(99)00072-4 · Cited by 219
Reovirus as an Oncolytic Agent Against Experimental Human Malignant Gliomas
Wilcox, M. E., Yang, W., Senger, D. L., Rewcastle, N. B., Morris, D. G., Brasher, P. M. A., Shi, Z. Q., Johnston, R. N., Nishikawa, S., Lee, P. W. K., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.12.903 · Cited by 218
Steiner, H. H., Bonsanto, M. M., Beckhove, P., Brysch, M., Geletneky, K., Ahmadi, R., Schuele-Freyer, R., Kremer, P., Ranaie, G., Matejic, D., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.038 · Cited by 216
MTH-68/H Oncolytic Viral Treatment in Human High-Grade Gliomas
Csatary, L. K., Gosztonyi, G., Szeberenyi, J., Fabian, Z., Liszka, V., Bodey, B., & Csatary, C. M. (2004) · Journal of Neuro-Oncology · doi:10.1023/b:neon.0000021735.85511.05 · Cited by 200
Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy.
Lorence, R. M., Katubig, B. B., Reichard, K. W., Reyes, H. M., Phuangsab, A., Sassetti, M., Walter, R. J., & Peeples, M. E. (1994) · PubMed · Cited by 156
Schirrmacher, V. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0602-0 · Cited by 124
Zeng, J., Fournier, P., & Schirrmacher, V. (2002) · Virology · doi:10.1006/viro.2002.1413 · Cited by 121
Oncolytic Viruses: Clinical Applications as Vectors for the Treatment of Malignant Gliomas
Shah, A. C., Benos, D. J., Gillespie, G. Y., & Markert, J. M. (2003) · Journal of Neuro-Oncology · doi:10.1023/b:neon.0000003651.97832.6c · Cited by 116
Clinical Trials of Adenoviruses in Brain Tumors: A Review of Ad-p53 and Oncolytic Adenoviruses
Vecil, G. G., & Lang, F. F. (2003) · Journal of Neuro-Oncology · doi:10.1023/b:neon.0000003653.45635.32 · Cited by 90
RIGging an antiviral defense—it's in the CARDs
Levy, D. E., & Marié, I. J. (2004) · Nature Immunology · doi:10.1038/ni0704-699 · Cited by 62
Umansky, V., Shatrov, V. A., Lehmann, V., & Schirrmacher, V. (1996) · International Immunology · doi:10.1093/intimm/8.4.491 · Cited by 55
Fournier, P., Zeng, J., & Schirrmacher, V. (2003) · International Journal of Oncology · doi:10.3892/ijo.23.3.673 · Cited by 46
Oncolytic viruses for the therapy of brain tumors and other solid malignancies a review
Chiocca, E. A. (2003) · Frontiers in bioscience · doi:10.2741/976 · Cited by 40
Slosaris, M., Levy, B., Katz, E., et al. (1989) · Avian Diseases · doi:10.2307/1590839 · Cited by 15
Cited by
Oncolytic viruses: a new class of immunotherapy drugs
Kaufman, H. L., Kohlhapp, F. J., & Zloza, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4663 · Cited by 1,642
Emerging therapies for glioblastoma: current state and future directions
Rong, L., Li, N., & Zhang, Z. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02349-7 · Cited by 510
Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress
Liu, T.-C., Galanis, E., & Kirn, D. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0736 · Cited by 450
Oncolytic viruses in cancer therapy
Vähä-Koskela, M. J. V., Heikkilä, J. E., & Hinkkanen, A. E. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.02.002 · Cited by 333
Glioblastoma at the crossroads: current understanding and future therapeutic horizons
Singh, S., Dey, D., Barik, D., Mohapatra, I., Kim, S., Sharma, M., Prasad, S., Wang, P., Singh, A., & Singh, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02299-4 · Cited by 287
Metadata
- Authors
- Freeman, A. I., Zakay-Rones, Z., Gomori, J. M., Linetsky, E., Rasooly, L., Greenbaum, E., Rozenman-Yair, S., Panet, A., Libson, E., Irving, C. S., Galun, E., & Siegal, T.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2006-01
- Volume
- 13
- Issue
- 1
- Pages
- 221-228
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2049092411
- Cited by
- 407
- References
- 31
- FWCI
- 6.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.